Wall Street Zen Downgrades LifeMD (NASDAQ:LFMD) to Sell

LifeMD (NASDAQ:LFMD) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research firms have also issued reports on LFMD. Loop Capital set a $10.00 target price on LifeMD in a report on Thursday, March 12th. Mizuho raised LifeMD from a “neutral” rating to an “outperform” rating and increased their price target for the company from $6.00 to $8.00 in a research report on Monday, March 16th. HC Wainwright lifted their price objective on LifeMD from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday. Finally, BTIG Research restated a “buy” rating and set a $10.00 target price on shares of LifeMD in a research note on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LifeMD presently has a consensus rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Price Performance

Shares of LFMD opened at $4.78 on Friday. The company has a market cap of $231.16 million, a P/E ratio of 95.62 and a beta of 2.03. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $15.84. The firm’s 50 day moving average price is $3.87 and its 200 day moving average price is $3.93.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. Research analysts forecast that LifeMD will post 0.01 earnings per share for the current year.

Institutional Trading of LifeMD

A number of institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of LifeMD in the 4th quarter valued at about $36,000. Magnus Financial Group LLC purchased a new stake in LifeMD during the fourth quarter worth approximately $41,000. R Squared Ltd acquired a new position in LifeMD in the first quarter valued at approximately $41,000. Jain Global LLC acquired a new position in LifeMD in the fourth quarter valued at approximately $45,000. Finally, Quarry LP purchased a new position in LifeMD in the third quarter valued at approximately $52,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.